{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:35:24Z","timestamp":1792496124606,"version":"4.5.0"},"reference-count":66,"publisher":"American Society of Hematology","issue":"25","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors are a class of antineoplastic therapies that unleash immune cells to kill malignant cells. There are currently 7 medications that have been approved by the US Food and Drug Administration for the treatment of 14 solid tumors and 2 hematologic malignancies. These medications commonly cause immune-related adverse effects as a result of overactive T lymphocytes, autoantibody production, and\/or cytokine dysregulation. Hematologic toxicities are rare and of uncertain mechanism, and therefore management is often based on experiences with familiar conditions involving these perturbed immune responses, such as autoimmune hemolytic anemia, immune thrombocytopenia, and idiopathic aplastic anemia. Management is challenging because one must attend to the hematologic toxicity while simultaneously attending to the malignancy, with the imperative that effective cancer therapy be maintained or minimally interrupted if possible. The purpose of this review is to help clinicians by providing a clinical and pathophysiological framework in which to view these problems.<\/jats:p>","DOI":"10.1182\/blood.2020009016","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T20:27:04Z","timestamp":1633465624000},"page":"3594-3604","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":138,"title":["Hematologic complications of immune checkpoint inhibitors"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6817-5761","authenticated-orcid":false,"given":"Michael H.","family":"Kroll","sequence":"first","affiliation":[{"name":"1Section of Benign Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-3929","authenticated-orcid":false,"given":"Cristhiam","family":"Rojas-Hernandez","sequence":"additional","affiliation":[{"name":"1Section of Benign Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-7307","authenticated-orcid":false,"given":"Cassian","family":"Yee","sequence":"additional","affiliation":[{"name":"2Department of Medical Melanoma Oncology,"},{"name":"3Department of Immunology, and"},{"name":"4Parker Institute of Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2022062315232713800_B1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"issue":"6","key":"2022062315232713800_B2","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"6029","key":"2022062315232713800_B3","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science."},{"issue":"5238","key":"2022062315232713800_B4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science."},{"issue":"3","key":"2022062315232713800_B5","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"9","key":"2022062315232713800_B6","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov."},{"issue":"2","key":"2022062315232713800_B7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2496","article-title":"The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood","volume":"14","author":"Sage","year":"2013","journal-title":"Nat Immunol."},{"issue":"1","key":"2022062315232713800_B8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells","volume":"96","author":"Sasidharan Nair","year":"2018","journal-title":"Immunol Cell Biol."},{"issue":"2","key":"2022062315232713800_B9","doi-asserted-by":"crossref","first-page":"e000873","DOI":"10.1136\/jitc-2020-000873","article-title":"Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines","volume":"8","author":"Park","year":"2020","journal-title":"J Immunother Cancer."},{"issue":"2","key":"2022062315232713800_B10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity."},{"key":"2022062315232713800_B11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coi.2021.02.002","article-title":"Adverse events induced by immune checkpoint inhibitors","volume":"69","author":"Perdigoto","year":"2021","journal-title":"Curr Opin Immunol."},{"issue":"2","key":"2022062315232713800_B12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cei.13421","article-title":"Mechanisms of checkpoint inhibition-induced adverse events","volume":"200","author":"Urwyler","year":"2020","journal-title":"Clin Exp Immunol."},{"key":"2022062315232713800_B13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/TCRM.S193338","article-title":"Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients","volume":"15","author":"Zhou","year":"2019","journal-title":"Ther Clin Risk Manag."},{"issue":"1","key":"2022062315232713800_B14","doi-asserted-by":"crossref","first-page":"10377","DOI":"10.1038\/s41598-020-67497-2","article-title":"Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis","volume":"10","author":"Yasuoka","year":"2020","journal-title":"Sci Rep."},{"key":"2022062315232713800_B15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2021.04.001","article-title":"Intestinal microbiota: a potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors","volume":"509","author":"Luo","year":"2021","journal-title":"Cancer Lett."},{"issue":"69","key":"2022062315232713800_B16","doi-asserted-by":"crossref","first-page":"114268","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget."},{"issue":"10","key":"2022062315232713800_B17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2020.07.035","article-title":"Toxicity in combination immune checkpoint inhibitor and radiation therapy: a systematic review and meta-analysis","volume":"151","author":"Sha","year":"2020","journal-title":"Radiother Oncol."},{"key":"2022062315232713800_B18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Cancer."},{"issue":"1","key":"2022062315232713800_B19","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol."},{"issue":"1","key":"2022062315232713800_B20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/CJI.0000000000000390","article-title":"Management and outcomes of hematological immune-related adverse events: systematic review and meta-analysis","volume":"45","author":"Wilson","year":"2022","journal-title":"J Immunother."},{"key":"2022062315232713800_B21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Cancer."},{"issue":"1","key":"2022062315232713800_B22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-017-0210-0","article-title":"Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy","volume":"5","author":"Shiuan","year":"2017","journal-title":"J Immunother Cancer."},{"issue":"12","key":"2022062315232713800_B23","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood."},{"key":"2022062315232713800_B24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","article-title":"Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review","volume":"196","author":"Solinas","year":"2020","journal-title":"Thromb Res."},{"issue":"5","key":"2022062315232713800_B25","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jth.15272","article-title":"Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Icht","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"17","key":"2022062315232713800_B26","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022062315232713800_B27","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"5","key":"2022062315232713800_B28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol."},{"issue":"2","key":"2022062315232713800_B29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios","year":"2019","journal-title":"Eur J Haematol."},{"issue":"10","key":"2022062315232713800_B30","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fphar.2019.00454","article-title":"Hematological side effects of immune checkpoint inhibitors: The example of immune-related thrombocytopenia","volume":"10","author":"Calvo","year":"2019","journal-title":"Front Pharmacol."},{"issue":"16","key":"2022062315232713800_B31","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood."},{"issue":"23","key":"2022062315232713800_B32","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"issue":"18","key":"2022062315232713800_B33","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer."},{"issue":"9","key":"2022062315232713800_B34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med."},{"issue":"6","key":"2022062315232713800_B35","doi-asserted-by":"crossref","first-page":"e0198184","DOI":"10.1371\/journal.pone.0198184","article-title":"Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice","volume":"13","author":"Depr\u00e9","year":"2018","journal-title":"PLoS One."},{"issue":"2","key":"2022062315232713800_B36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/CJI.0000000000000293","article-title":"Immune-related neutropenia following treatment with immune checkpoint inhibitors","volume":"43","author":"Finkel","year":"2020","journal-title":"J Immunother."},{"issue":"1","key":"2022062315232713800_B37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s12885-020-06763-y","article-title":"Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect","volume":"20","author":"Boegeholz","year":"2020","journal-title":"BMC Cancer."},{"issue":"1","key":"2022062315232713800_B38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3960\/jslrt.20047","article-title":"Acquired amegakaryocytic thrombocytopenia after durvalumab administration","volume":"61","author":"Suyama","year":"2021","journal-title":"J Clin Exp Hematop."},{"issue":"5","key":"2022062315232713800_B39","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjh.16630","article-title":"Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review","volume":"189","author":"Dupr\u00e9","year":"2020","journal-title":"Br J Haematol."},{"issue":"23","key":"2022062315232713800_B40","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"La Ros\u00e9e","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2022062315232713800_B41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/jmedgenet-2018-105485","article-title":"Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism","volume":"56","author":"Al-Samkari","year":"2019","journal-title":"J Med Genet."},{"issue":"3","key":"2022062315232713800_B42","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.mayocp.2020.05.045","article-title":"Incidence and risk of various types of arterial thromboembolism in patients with cancer","volume":"96","author":"Wang","year":"2021","journal-title":"Mayo Clin Proc."},{"issue":"4","key":"2022062315232713800_B43","first-page":"423","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","volume":"2","author":"Roopkumar","year":"2021","journal-title":"Med (NY)."},{"issue":"4","key":"2022062315232713800_B44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.it.2021.02.006","article-title":"Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines","volume":"42","author":"Kang","year":"2021","journal-title":"Trends Immunol."},{"issue":"1","key":"2022062315232713800_B45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/imr.12349","article-title":"Human IgG4: a structural perspective","volume":"268","author":"Davies","year":"2015","journal-title":"Immunol Rev."},{"issue":"4","key":"2022062315232713800_B46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med."},{"issue":"31","key":"2022062315232713800_B47","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol."},{"issue":"34","key":"2022062315232713800_B48","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022062315232713800_B49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-020-00947-6","article-title":"Targeting immune checkpoints in hematological malignancies","volume":"13","author":"Salik","year":"2020","journal-title":"J Hematol Oncol."},{"issue":"8","key":"2022062315232713800_B50","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/s41409-021-01268-z","article-title":"Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review","volume":"58","author":"Bobillo","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"2022062315232713800_B51","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3390\/cancers13071532","article-title":"Autoimmune complications in hematologic neoplasms","volume":"13","author":"Barcellini","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"2","key":"2022062315232713800_B52","doi-asserted-by":"crossref","first-page":"e001818","DOI":"10.1136\/jitc-2020-001818","article-title":"Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia\/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Saberian","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"12","key":"2022062315232713800_B53","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1002\/art.41064","article-title":"Is immune checkpoint inhibitor treatment an option for patients with rheumatic diseases and cancer?","volume":"71","author":"Buckley","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"26","key":"2022062315232713800_B54","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood."},{"issue":"1","key":"2022062315232713800_B55","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"9","key":"2022062315232713800_B56","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"2022062315232713800_B57","doi-asserted-by":"crossref","first-page":"e000604","DOI":"10.1136\/jitc-2020-000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","journal-title":"J Immunother Cancer."},{"issue":"1","key":"2022062315232713800_B58","doi-asserted-by":"crossref","first-page":"e000144","DOI":"10.1136\/jitc-2019-000144","article-title":"Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma","volume":"8","author":"Abou Alaiwi","year":"2020","journal-title":"J Immunother Cancer."},{"issue":"2","key":"2022062315232713800_B59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat Rev Immunol."},{"issue":"21","key":"2022062315232713800_B60","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med."},{"key":"2022062315232713800_B61","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","article-title":"Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation","volume":"63","author":"Ferris","year":"2018","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"2022062315232713800_B62","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1535-7163.MCT-21-0041","article-title":"Innate immune checkpoint inhibitors: the next breakthrough in medical oncology?","volume":"20","author":"Lentz","year":"2021","journal-title":"Mol Cancer Ther."},{"issue":"25","key":"2022062315232713800_B63","doi-asserted-by":"crossref","first-page":"17675","DOI":"10.18632\/oncotarget.24832","article-title":"A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies","volume":"9","author":"Vey","year":"2018","journal-title":"Oncotarget."},{"issue":"3","key":"2022062315232713800_B64","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41375-020-0939-1","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies","volume":"35","author":"Armand","year":"2021","journal-title":"Leukemia."},{"issue":"12","key":"2022062315232713800_B65","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human first-in-class phase I trial of the anti-CD47 antibody Hu59F-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol."},{"key":"2022062315232713800_B66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.3068","article-title":"A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anti-cancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma [abstract]","volume":"36","author":"Lakhani","year":"2018","journal-title":"J Clin Oncol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/25\/3594\/1903576\/bloodbld2020009016c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/25\/3594\/1903576\/bloodbld2020009016c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T11:25:42Z","timestamp":1655983542000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/25\/3594\/477166\/Hematologic-complications-of-immune-checkpoint"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":66,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2022,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020009016","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}